Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547014 · ClinicalTrials.gov registry record · Phase 1
First Safety Study in Humans of a Single Dose of CPG 52364
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT00547014: Completed Phase 1 study, sponsored by Pfizer.
NCT00547014 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 61 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547014, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.
Interventions
- DRUG Placebo Comparator: Cohort 1 Placebo
- DRUG 52364 3 mg
- DRUG Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
- DRUG 52364 10 mg
- DRUG 52364 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00547014 record still lists
NCT00547014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Placebo Comparator: Cohort 1 Placebo is the first listed.
NCT00547014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00547014 about?
NCT00547014 is a clinical study titled "First Safety Study in Humans of a Single Dose of CPG 52364". Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.
What is the current status of trial NCT00547014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2007-09. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00547014?
The interventions under investigation include: Placebo Comparator: Cohort 1 Placebo (DRUG), 52364 3 mg (DRUG), Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo (DRUG), 52364 10 mg (DRUG), 52364 30 mg (DRUG).
Who is sponsoring clinical trial NCT00547014?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547014's enrollment target sits among peer trials
61 828th of 2000 higher than 1,170 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia